Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
survival rates
6, 12 months
Yes
jinqing li, MD
Study Director
cancer canter sun yat-set university
China: Ministry of Health
TACE1
NCT00646100
July 2007
February 2010
Name | Location |
---|